Jason Brunetta

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Brief Report

David A. Wohl, Shinichi Oka, Nathan Clumeck et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 179 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults

Sharon Walmsley, Anchalee Avihingsanon, Jihad Slim et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 115 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial

Chloe Orkin, Jean‐Michel Molina, Eugènia Negredo et al. · The Lancet HIV · 2017 · 96 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial

Onyema Ogbuagu, Peter Ruane, Daniel Podzamczer et al. · The Lancet HIV · 2021 · 91 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17